- An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand
-
Sarojvisut P, Apisarnthanarak A, Jantarathaneewat K, Sathitakorn O, Pienthong T, Mingmalairak C, Warren DK, Weber DJ
- KMID: 2541531
- Infect Chemother.
- 2023 Mar;55(1):50-58.
- doi: 10.3947/ic.2022.0127
Background: The role of ivermectin in the treatment of moderate coronavirus disease 2019 (COVID-19) is controversial. We performed an open label randomized controlled trial to evaluate the role of ivermectin plus... -
- CITED
-
- Close
- SHARE
-
- Close
